Home Blog Page 1282

IBM Introduces New Software to Address Growing Digital Sovereignty Imperative

Purpose-built to enable organizations to deploy their own secured, compliant and automated environments for AI-ready sovereign workloads

ARMONK, N.Y., Jan. 15, 2026 /PRNewswire/ — IBM (NYSE: IBM) today announced IBM Sovereign Core, the industry’s first AI-ready sovereign-enabled software for enterprises, governments and service providers to build, deploy and manage AI-ready sovereign environments. Organizations around the world are facing a growing imperative to exercise control over their technology infrastructure. Driven by evolving regulatory requirements, and the need for auditable governance, enterprises and governments are seeking self-managed environments where they maintain complete operational authority, particularly as they deploy AI workloads that amplify sovereignty concerns.

IBM Corporation logo.
IBM Corporation logo.

Digital sovereignty goes beyond data residency. It encompasses who operates and controls the technology environment, how data is accessed and governed, where workloads execute, and under whose jurisdiction AI models run. Yet most organizations lack a destination to land, modernize, and re-host applications under sovereign control, including applications that will incorporate AI capabilities, and have continuous compliance reporting capabilities. “Gartner® predicts that more than 75% of all enterprises will have a digital sovereignty strategy by 2030, often sovereign cloud strategies1.”

“Businesses are facing growing pressure to innovate while meeting tightening regulatory requirements and recognizing the importance of controlling how sensitive data and AI workloads are accessed and operated,” said Priya Srinivasan, General Manager, IBM Software Products. “This shift is creating an urgent need for sovereign solutions that deliver AI-ready environments. With IBM Sovereign Core, we are helping clients move faster and with confidence— combining openness, compliance, and operational autonomy to meet the demands of the AI era, without the need to sacrifice sovereignty requirements.”

Sovereignty as a Software Foundation

IBM Sovereign Core will help customers achieve verifiable sovereignty and full operational control. Sovereign Core is purpose-built software to build, deploy, and manage cloud-native and AI workloads under an organization’s own authority, within chosen jurisdictions, built on Red Hat’s open source foundation. Unlike approaches that layer sovereignty controls onto existing architectures, Sovereign Core makes sovereignty an inherent property of the software itself. Organizations can gain:

  • Customer-operated control plane: organizations maintain direct operational authority over software operations, deployment decisions, and system configurations without intermediation from a vendor not in region.
  • In-boundary identity and keys: all authentication, authorization, encryption keys, and access management remain within jurisdiction boundaries under customer control.
  • Ongoing compliance enablement and generated evidence of continuous compliance: comprehensive operational data, system telemetry, and audit trails are generated, stored, and managed within the sovereign boundary, including automated identity.
  • Governed AI inference: AI model deployment and hosting, local GPU clusters, local inference execution and agent operations occur under local governance with traceability and oversight, without exporting data to external providers.
  • Ease of deployment: delivering sovereignty at scale with consistency and flexibility allowing organizations to stand up isolated environments with built-in multitenancy capabilities within a matter of days of deployment; choice of hardware and infrastructure.

“The sovereign AI conversation has focused on data residency, but that’s only part of the equation,” said Sanjeev Mohan, Principal, SanjMo. “IBM Sovereign Core addresses the harder question: who controls the system and can you prove it to regulators? IBM takes a holistic approach spanning data, operations, technology, and assurance, with continuous monitoring. As AI moves into production, that kind of ongoing accountability becomes non-negotiable.”

“AI is accelerating the pace at which sovereignty questions move from theory to daily operations,” said Erik Fish, Director of Geotechnology at Eurasia Group. “As geopolitics, regulation, and data governance increasingly converge, governments and enterprises must move while demonstrating clear control over critical data and infrastructure. The challenge is no longer a trade-off between openness and sovereignty, but governing data, access, and infrastructure amid growing regulatory and geopolitical constraints.” 

Operational Independence Through Environment Choice

Customers can deploy IBM Sovereign Core in the environment of their choice – whether in on-premises data centers, supported in-region cloud infrastructure or through IT Service Providers. IBM is collaborating with IT Service Providers globally, starting with an initial rollout in Europe with Cegeka in Belgium and the Netherlands and Computacenter in Germany. These partnerships allow local operational independence and compliance management, while enabling IT Service Providers to offer differentiated sovereign services to enterprises preparing for and running AI-scale workloads.

“As organizations navigate increasingly complex compliance and regulatory requirements, we’re seeing strong demand for digital platforms and software that allows sensitive data to remain within controlled, compliant boundaries,” said Gaetan Willems, VP Cloud & Digital Platforms, Cegeka. “Partnering with IBM to offer a pre-architected solution through our in-country environment enables us to deliver enterprise-ready software to our clients, while allowing them to address local compliance standards.”

“With IBM Sovereign Core, we can focus on configuring the software to each client’s specific use cases rather than spending months piecing together disparate components and validating sovereignty controls,” said Christian Schreiner, Unit Director Cloud, Computacenter. “It can significantly accelerate our time-to-value and let us help clients who previously couldn’t consider AI solutions at all.”

IBM Sovereign Core Availability

Starting in February, IBM Sovereign Core will be available in tech preview, with full general availability planned for mid-year 2026. At GA, additional capabilities will be introduced.

To learn more about IBM Sovereign Core, read our blog here, and join us virtually for the IBM Tech Summit, January 27, register here.  To join the waitlist for IBM Sovereign Core Tech Preview, visit here.

IBM’s statements regarding its plans, directions, and intent are subject to change or withdrawal without notice at IBM’s sole discretion. Information regarding potential future products is intended to outline our general product direction and it should not be relied on in making a purchasing decision.

About IBM

IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. Thousands of government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM’s hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM’s breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM’s long-standing commitment to trust, transparency, responsibility, inclusivity and service. Visit www.ibm.com for more information.

1 Gartner, The Future of Cloud in 2030: AI-Enabling Cloud Services. 6 August 2025, Dennis Smith. Al. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.

Contact:
Michele Brancati
mbrancati@ibm.com

AI Can Unlock $4.5 Trillion in U.S. Labor Productivity Today, Reveals Cognizant’s Latest “New Work, New World 2026” Report

Cognizant’s study shows AI is accelerating faster than projected, with 93% of jobs potentially affected today

Findings also point to the limits of AI’s impact, with skilling and human judgment playing a critical role in how organizations capture AI’s full value

TEANECK, N.J., Jan. 15, 2026 /PRNewswire/ — Cognizant today announced the release of “New Work, New World 2026,” providing fresh analysis on how artificial intelligence (AI) will impact work and jobs. Building on the original report’s release in 2024, the new research reveals AI is changing the workforce faster than previously reported: it’s now capable of handling $4.5 trillion in U.S. work tasks and impacting potentially 93% of jobs today. However, the report also underscores that AI is not a blanket solution for advancing labor productivity: human involvement and adaptable operations continue to be vital to capturing the full value potential of AI.

Cognizant's new research reveals AI is changing the workforce faster than previously reported, but humans are still essential.
Cognizant’s new research reveals AI is changing the workforce faster than previously reported, but humans are still essential.

Cognizant’s analysis for New Work, New World 2026 is based on a reassessment of 18,000 tasks and 1,000 jobs in the O*NET labor database, with a focus on how jobs and tasks could be assisted or automated by AI. Specifically, the new study points to an accelerated pace of change in “exposure scores”—the degree to which a job can be assisted or automated by AI—and highlights how those evolving changes can influence labor and enterprise success.

“We’re seeing significant capital flow into AI, and the rapid adoption of these technologies is reshaping the workplace,” says Ravi Kumar S, CEO of Cognizant. “Our research shows that enterprises could unleash $4.5 trillion in labor productivity today. However, turning that investment into meaningful results takes more than raw technology power. Businesses must also integrate contextual intelligence, build flexible systems that can absorb new AI capabilities, and prioritize human learning and development alongside technological advancements. Companies that focus on these essentials will unlock the true value of AI.”

Kumar continues: “Human skilling becomes the bridge through which today’s AI spending translates into tomorrow’s tangible results. AI’s promise is realized when we empower our workforce with digital fluency, adaptability and continuous learning, while ensuring AI solutions are deeply contextualized to unique business challenges. As a result, new job roles will emerge to harness this opportunity.”

Cognizant’s “New Work, New World 2026” report reaffirms that human knowledge and judgment remain essential to harnessing AI’s full potential. It emphasizes that much of AI’s value potential remains untapped without the power of human intelligence and involvement. There is still much work left to be done by human hands across job tasks that AI may never assist with, let alone automate. The potential of AI resides in skilling workers and freeing them up for higher order thinking—creative agility, fresh thinking and novel ideas that can transform business operations. 

Other key highlights from the report’s findings include:

  • AI is changing theworkforce far more quickly than projected: The report finds the average exposure score across jobs is 39% today, which is 30% higher than what the original forecast was for 2032. This means more tasks can be assisted or automated by AI, sooner than originally predicted. These exposure scores are also now increasing by 9% annually, compared with 2% in the original research. Some notable changes in exposure scores across jobs include legal (from 9% to 63%), education (from 11% to 49%), healthcare practitioners (from 10% to 39%) and C-suite roles, including CEO (from 25% to 60%).
  • Knowledge work is not disappearing, nor is manual work completely insulated: The impact of AI is evolving across sectors. Roles in computer and mathematics, once seen as highly exposed to AI, no longer top the report’s exposure scores – indicating rapid advancements in AI may have reached their limits in some knowledge work areas. Meanwhile, the research reveals AI could significantly impact manual labor jobs at a faster rate than previously understood. For example, the exposure score for transportation rose from 6% to 25%, and in construction it rose from 4% to 12%.
  • All told, AI can perform $4.5T in labor productivity today across a wide variety of roles: Through increased automation, AI has the potential to deliver significant value to businesses and the economy today. According to the new report, fewer tasks are left untouched by automation. The percentage of tasks that are non-automatable by AI has plummeted, from 57% on average across tasks in 2023 to 32% today.
  • Simultaneously, realizing full AI value from labor is not a one-size-fits-all strategy: The report revealed AI is unable to automate upwards of 40% of management, business/ financial operations and administrative tasks, signaling a critical reality: AI alone can’t fully replace humans, and human expertise and collaboration remain indispensable. To tap into the $4.5T in labor productivity, businesses must create flexible operating models that can adapt to new and evolving AI capabilities. They must also treat workforce learning as a rapid response mechanism so employees can continuously keep pace with change and effectively leverage AI to deliver meaningful growth.

To read the full report, visit the website here.

About Cognizant:
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we’re improving everyday life. See how at www.cognizant.com or @cognizant.

Cognizant remains committed to empowering the next generation of talent through its Synapse program, which aims to reach two million individuals globally by 2030, creating new pathways to opportunity and preparing the workforce for the jobs of the future. To learn more about Cognizant’s Synapse skilling initiative, visit the website here.

Forward-Looking Statements

This press release includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties and assumptions as to future events that may not prove to be accurate. These statements include, but are not limited to, express or implied forward-looking statements relating to the adoption of AI and the labor value of such adoption, the effects and speed of impact of AI on the workforce and the economy and the effectiveness of businesses’ efforts to capture the full potential of AI through skilling and human involvement. These statements are neither promises nor guarantees but are the findings of the studies discussed above and remain subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Factors that could cause outcomes to differ materially from those expressed or implied include general economic conditions, the impact of technological development and competition, the competitive and rapidly changing nature of the markets we compete in, the competitive marketplace for talent and its impact on employee recruitment and retention, and the other factors discussed in our most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Cognizant undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities law.

For more information, contact:

US

Gabby Gugliocciello

Email gabrielle.gugliocciello@cognizant.com

Europe / APAC

Sarah Douglas

Email sarah.douglas@cognizant.com

India

Vipin Nair

Email Vipin.nair@cognizant.com

 

New Cognizant Logo

oToBrite at Automotive World Tokyo 2026: Vision-AI Powering ADAS and Autonomous Driving to Enhance Passenger Safety

HSINCHU, Jan. 15, 2026 /PRNewswire/ — oToBrite is showcasing its Vision-AI–based automotive solutions at Automotive World Tokyo 2026, highlighting intelligent perception technologies that support ADAS and autonomous driving applications, while continuing to enhance passenger safety.

At the exhibition, oToBrite presents its 1–8MP automotive-grade GMSL2 camera module portfolio, designed to address imaging requirements across commercial vehicles, passenger cars, unmanned vehicles, and robotics.

On the system level, oToBrite showcases its advanced Level 4 Vision-AI technologies for closed environments, integrating non-semantic and semantic VSLAM to support a wide range of parking environments, including both indoor and outdoor parking facilities. Through this fusion approach, the system enables memory-based mapping, vehicle localization, and vehicle summon functions, demonstrating Vision-AI as a core technological advantage in intelligent parking and autonomous driving applications.

A key highlight at the booth is SafeZone, oToBrite’s CES Innovation Award–winning Vision-AI anti-pinch sensing system for bus doors, which extends Vision-AI applications from vehicle safety into real-world passenger environments.

Designed specifically to enhance bus door safety, SafeZone uses AI-based image recognition to accurately detect passengers even in crowded conditions, when umbrellas are present, or when only parts of the body are visible. The system effectively reduces the risk of door-related injuries and has already been deployed by public bus operators in Taiwan.

Among other system solutions, oToGuard 2.0 is the world’s first single-platform solution capable of fully supporting Level 0 to Level 2+ ADAS, while complying with major international regulations, including UN R130, R151, R158, R159, and UN R79 (CSF, ACSF-B1, ESF, ACSF-C). The solution delivers comprehensive safety and intelligent driving capabilities for commercial fleets, heavy-duty vehicles, and electric buses.

For robotics and unmanned vehicle applications, oToSLAM enables high-precision positioning and 3D environmental perception using Vision-AI technology with four Around View Monitoring (AVM) camera modules and a single ECU, effectively accelerating autonomous driving deployment in specialized application scenarios.

Notably, in the passenger vehicle segment, oToParking integrates both the mass-produced Automated Parking Assist (APA) function and the fully developed Autonomous Valet Parking (AVP) function into its solution, enabling Level 4 autonomous driving in low-speed, closed environments.

As autonomous driving continues to evolve, and as visual perception demands increase across passenger vehicles, commercial vehicles, unmanned vehicles, and robotics, all featured products and Vision-AI technologies are on display at Automotive World Tokyo 2026, Booth W5-41.

oToBrite showcases GMSL2 cameras and vision-AI solutions at Automotive World 2026.
oToBrite showcases GMSL2 cameras and vision-AI solutions at Automotive World 2026.

 

Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience

SINGAPORE, Jan. 15, 2026 /PRNewswire/ — Today, Visa, a world leader in digital payments, announced its support for Chinese Visa cardholders to pay with Apple Pay. Together with Apple, Visa will enable Chinese cardholders to add Visa cards[1] from participating banks to Apple Pay and make payments at overseas Visa-accepting merchants, in-store, in-app and online. Today, 79 percent[2] of in-person transactions globally are made contactlessly with NFC.

Yin Xiaolong, General Manager at Visa Mainland China, said: “As global digital payments develop rapidly, consumers increasingly expect mobile payment solutions that are smartphone-based and interoperable. Visa has long been committed to providing Chinese cardholders with diverse payment options, enabling them to enjoy a secure and seamless payment experience wherever they are. Upholding our long‑standing commitment to the Chinese market and to our cardholders, Visa is increasing its investments in data and payment security, launching tokenization services and taking the lead in enabling their use in cross‑border scenarios. We are delighted to work with Apple and financial institutions to bring Chinese cardholders a safer and more convenient new mobile payment experience.”

The first batch of supporting issuing banks includes Industrial and Commercial Bank of China, Bank of China, Agricultural Bank of China, Bank of Communications, China Merchants Bank, China CITIC Bank, Ping An Bank and Industrial Bank. Visa and Apple are working closely with more banking partners, including Shanghai Pudong Development Bank, China Construction Bank, China Minsheng Bank and China Everbright Bank, and related features will be rolled out in the future.

Easy Payments Online and Offline

When using Apple Pay for in-store payments, consumers simply double-click the side button, authenticate, and hold their iPhone or Apple Watch near the payment terminal for contactless payment. Every Apple Pay transaction requires secure authentication using Face ID, Touch ID, or device passcode, and the result is sent to the issuing bank as a one-time dynamic security transaction code, putting transaction security firmly in the hands of the consumer.

Consumers can also use Apple Pay on iPhone and iPad for faster, more convenient payments in overseas mobile apps or online websites, without the need to create accounts or repeatedly entering contact information, card numbers, shipping, and billing details.

Built-in Privacy and Security Protection

Security and privacy are at the core of Apple Pay. When adding Visa cards, the actual card number is neither stored on the device nor on Apple’s servers. Instead, the system assigns a unique Device Account Number generated using Visa’s tokenization technology, encrypts it, and stores it securely in the device’s Secure Element. This is an industry-standard certified chip designed specifically to securely store payment information on the device.

Quick Setup, Easy to add  Visa Cards

Setting up Apple Pay is simple. Open the Wallet app on your iPhone, tap the plus sign, then follow the prompts to navigate to your bank’s app and add your Visa card, or add your Visa card directly to Apple Wallet via your bank’s app. Once the card is added to your iPhone, Apple Watch, or iPad, you can immediately start using Apple Pay on that device.

Cardholders continue to enjoy the same rewards and benefits as with their physical cards. In addition, Visa has launched exclusive offers such as first-time binding bonuses and transportation perks, covering travel abroad and overseas living scenarios. Cardholders can visit the Visa “V Select” WeChat Mini Program for more information on benefits.

For more information about Visa, please visit: www.visa.cn/pay-with-visa/featured-technologies/applepay.html

For more information about Apple Pay, please visit: https://www.apple.com/cn/apple-pay/

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, sellers, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.cn.

[1]The first batch of supporting issuing banks includes Industrial and Commercial Bank of China (credit card), Bank of China (credit card), Agricultural Bank of China (credit card), Bank of Communications (credit card), China Merchants Bank (credit card), China CITIC Bank (credit and debit card), Ping An Bank (credit) and Industrial Bank (credit card).

[2] Visa’s 2025 Annual Report: s29.q4cdn.com/385744025/files/doc_downloads/2025/Visa-Fiscal-2025-Annual-Report.pdf

 

Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease

SHANGHAI, Jan. 15, 2026 /PRNewswire/ — AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AB-1009, an investigational adeno-associated virus (AAV) gene therapy being developed for the treatment of late-onset Pompe disease. With this announcement, the AB-1009 program advances to Phase 1/2, and AskBio initiates a clinical trial in the United States to explore the safety of AB-1009. The company anticipates recruiting its first patient in early 2026 [1].

In September 2024, Belief BioMed (BBM) and AskBio entered astrategic collaboration to explore the potential for new gene therapies [2]. BBM granted AskBio a sublicense to use the proprietary AAV capsid in the AB-1009 program and provided AAV vector production services. Within the collaborative development framework, BBM worked closely with the AskBio team, and its contributions were instrumental to the IND acceptance. 

Dr. Xiao Xiao, Co-founder, Chairman and Chief Science Officer of Belief BioMed, said, “We are delighted to learn that our partner AskBio has received IND acceptance for its gene therapy. This marks a significant milestone in our strategic collaboration and represents a practical achievement in globalized innovation within the gene therapy field. On behalf of Belief BioMed, I extend our sincere congratulations to the AskBio team! This IND acceptance reflects AskBio’s outstanding R&D capabilities and efficient clinical advancement, while also demonstrating the strong synergy between our technological resources and platforms. Looking ahead, Belief BioMed hopes to deepen our collaboration with AskBio to accelerate the global development of innovative therapies.”

About Pompe Disease

Pompe disease is an inherited lysosomal storage disorder caused by deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced or absent levels of GAA lead to accumulation of glycogen in cells, which is believed to result in the clinical manifestations of Pompe disease. The disease can be debilitating and is characterized by severe muscle weakness that worsens over time and is accompanied by diaphragmatic involvement, leading to respiratory insufficiency early in the course of the disease. Pompe disease ranges from a rapidly fatal infantile form with significant impacts to heart function, to a more slowly progressive, late-onset form primarily affecting skeletal muscle. It is estimated that Pompe disease affects approximately 5,000 to 10,000 people worldwide.

References

1. https://www.askbio.com/
2. https://www.beliefbiomed.com/newsd-749.html 

About Belief BioMed

Belief BioMed Inc. (BBM) is a global biotech company that integrates the research and development, manufacturing and clinical application of gene therapy products. The company is committed to providing innovative and more effective gene therapies for severe genetic and chronic diseases through safe and efficient viral vector technology. BBM has developed hundreds of key vector technologies, including HEK293 cell suspension serum-free culture process and full-scale chromatography purification process, and has established a commercial production platform for gene therapy drugs. The company has been building up its capabilities in a variety of fields including novel AAV capsids targeting different tissues, efficient transgene expression cassette design, and advanced clinically applicable vector manufacturing process. It has also established an extensive R&D pipeline covering a wide range of unmet clinical needs in different therapeutic areas such as hemophilia, DMD, Parkinson’s disease, osteoarthritis, etc. Several product pipelines have entered clinical studies or submitted IND filings. The Biologics License Application (BLA) of a gene therapy for the treatment of adult patients with hemophilia B, has been approved by the NMPA of China. For more information, visit www.beliefbiomed.com.

Statement

This information is only for the purpose of introducing the company’s event and information on that date, and is not intended to promote any company’s products and/or services, nor should it be construed as providing any advice or recommendation on the selection of any drugs, medical devices and treatment options.

For information about any company products, diseases and/or treatments, please consult a healthcare professional.

AB-1009 described herein has not been approved for marketing.

CLO Secures Final Victory in Software Copyright Infringement Case Against Style3D; Court Recognizes Large-Scale Commercial Piracy

SHANGHAI, Jan. 15, 2026 /PRNewswire/ — CLO Virtual Fashion (“CLO”), a leading provider of 3D fashion technology and end-to-end digital solutions, today announced that it has obtained a final and binding judgment from the Zhejiang Provincial High People’s Court in a computer software copyright infringement lawsuit against Zhejiang Lingdi Digital Technology Co. Ltd. (“Linctex”), the company behind Style3D. This ruling brings closure to a multi-year legal dispute, providing robust judicial protection for CLO’s core intellectual property. It underscores China’s firm commitment to strengthening IP protection and improving the business environment, while setting a significant industry benchmark for fair competition.

According to the final judgment by the Zhejiang Provincial High People’s Court, after thorough examination, the court clearly established that Linctex engaged in willful infringement by “prolonged, large-scale, and frequent” use of cracked versions of CLO software in its commercial operations. This activity directly infringed upon CLO’s legally protected computer software copyright. The court lawfully dismissed Linctex’s “fair use” defense, clarifying that the use had a direct commercial purpose. The judgment is now legally effective, providing final and comprehensive judicial protection for CLO’s legitimate rights and interests.

“We sincerely respect and thank the Chinese judicial authorities affirming the severity of the violations. This outcome fully reflects the importance China places on intellectual property protection. It sends a crucial signal to the entire industry about respecting and adhering to the rules, and it strengthens our convictions about deepening our commitment to the Chinese market,” said Simon Kim, CEO of CLO Virtual Fashion. “We pursued this case to protect not only our own innovations but the stability of the entire digital fashion ecosystem. Brands and companies need to know that the tools they rely on are stable, secure, and built on sound foundations.”

Kim further emphasized, “CLO’s commitment to the Chinese market is long-term and steadfast. Moving forward, we will continue to empower the digital transformation of China’s fashion industry through localized product development, responsive technical support, and deep collaboration with ecosystem partners.”

Linctex has been ordered to immediately cease all infringing activities and compensate CLO. CLO remains committed to its global anti-piracy efforts, ensuring a fair, competitive, and secure environment for all creators and enterprises in the digital fashion space.

About CLO Virtual Fashion

Evolved from the word “clothing”, CLO Virtual Fashion has been transforming and innovating the way people communicate and consume fashion since its launch in 2009. With more than 15 years of research and development in garment simulation, the company is leading the market by digitally merging, consolidating, and converging all components related to digital garments through its state-of-the-art 3D Cloth Simulation Algorithm. From 3D garment design software, digital asset management and design development collaborative platforms, all of CLO Virtual Fashion’s products and services are interconnected to provide clients and users with a more consolidated experience.

 

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

  • Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects
  • 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients
  • Complex modalities are WuXi Biologics’ core growth engine, with 2/3 of the new integrated projects comprising bispecific/multispecific antibodies and ADCs
  • Bispecific/multispecific antibodies are WuXi Biologics’ most exciting, fastest‑growing and highest‑margin engine. With 196 projects in the pipeline, this modality contributes nearly 20% of the company’s revenue and delivers 120%+ YoY growth
  • Scaling integrated CRDMO capabilities across the U.S. and Asia, while expanding the global network into the Middle East

SAN FRANCISCO, Jan. 15, 2026 /PRNewswire/ — On January 14, Dr. Chris Chen, CEO of WuXi Biologics, delivered a keynote at the 44th J.P. Morgan Healthcare Conference, highlighting the company’s 2025 achievements and outlining its outlook.

Dr. Chen commented, “Through the CRDMO model, we have achieved significant advancements spanning discovery, development, and manufacturing. By executing our ‘Follow and Win the Molecule’ strategy, world-class quality systems, deep technical capabilities and operational excellence, WuXi Biologics has become the partner of choice for biopharmaceutical innovators and MNCs. With the launch of the CRDMO+ strategy, we will further enable client success by scaling global manufacturing capacity, advancing modality innovation, and accelerating speed and execution.”

Strong Project Funnel Achieving Record High

Building on leading technology, proven execution and expanding global reach, WuXi Biologics added 209 new integrated projects in 2025, increasing the total to 945 and reinforcing its position as the partner of choice for biopharma innovators worldwide. Approximately half of the new projects originated from U.S. clients, underscoring strong client trust from the market. 

The company has excelled in three key areas—bispecific/multispecific antibodies, ADCs, and mAbs—leveraging its deep expertise and fully integrated end-to-end capabilities.

Bispecific/multispecific antibody and ADC projects continued to expand rapidly, with each growing by approximately 30% to reach 196 and 252 projects, respectively. Together, these complex modalities now account for nearly 50% of the total pipeline, underscoring strong demand for differentiated biologics. In parallel, the company maintains a deep and diversified base of over 400 mAbs and other protein therapeutics, including multiple multi-billion-dollar franchises in late-stage development and commercial manufacturing. With strength across research, development, manufacturing, bispecific/multispecific antibodies represent WuXi Biologics’ most exciting, fastest-growing and highest‑margin modality, contributing nearly 20% of the company’s revenue and achieving YoY growth exceeding 120%.

Through its “Win-the-Molecule” strategy, WuXi Biologics has been securing a quantity of projects across different stages. In 2025, the company added 23 projects, including 6 Phase III and commercial projects. Notably, half of these projects involve complex modalities, led by bispecific/multispecific antibodies and ADCs.

Research: Accelerating Deal Momentum and Platform Inflection

Research services maintained strong momentum from 2024 into 2025, with accelerating T‑cell engager (TCE) deals highlighting an inflection point for the company’s CD3 platform.

The CD3 platform enables bispecific antibodies to retain potent tumor-killing activity against target cells while minimizing cytokine release, optimizing the efficacy-safety balance. It has been widely adopted within the industry, including Merck, GSK, Chia Tai Tianqing Pharmaceutical, and Zai Lab.

WuXi Biologics’ research services business achieved another record year in 2025, securing record-breaking upfront payments and potential milestone values exceeding USD 4 billion.

Development: Pioneering Innovative Solutions

WuXi Biologics continues to expand its integrated services through new technology solutions that accelerate timelines, improve product quality and ensure scalable manufacturing.

It launched WuXia™ TrueSite, an industry-leading targeted integration (TI)-based CHO cell line platform designed to reshape biologics development by accelerating timelines, enhancing product quality, and ensuring consistent scalability for antibody and complex protein therapies. The platform has achieved an average mAb titer exceeding 8.0 g/L, with over 99% of clonal cell lines maintaining stable protein expression after passaging for 60 generations.

The company has also expanded core technology solutions for high-dose delivery into clinical and commercial applications, including High-throughput formulation development platform WuXiHighTM, Hyaluronidase Co-Formulation platform, and large-volume devices capabilities.

Manufacturing: Advancing Growth at Speed and Scale

As the “Follow and Win the Molecule” strategy continues, the total number of Phase III clinical and commercial manufacturing projects reached 99 in 2025. Manufacturing is positioned for accelerated growth, driven by an expanding commercial portfolio and revenue ramp per program over time.

Built on operational excellence, technology leadership and a proven quality system, WuXi Biologics completed 28 PPQs in 2025 and has 34 PPQs scheduled for 2026 based on current contracts, reflecting strong momentum in CMO services. It has achieved a 99%+ success rate on PPQ batches, ranking among the industry’s top performers. Since 2017, it has delivered more than 350 large‑scale batches (6,000 L – 16,000 L per batch) for global partners.

WuXi Biologics has consistently demonstrated a proven track record of adherence to the industry’s rigorous quality standards. As of the end of 2025, the company had successfully passed 46 regulatory inspections, including 22 inspections conducted by the FDA and EMA. The company also holds an industry-leading record with a 100% pass rate for FDA Pre-License Inspection (PLI). In addition, WuXi Biologics passed more than 1,800 GMP quality audits led by clients, including over 230 audits by EU Qualified Persons. Currently, the company operates 15 GMP-certified drug substance and drug product facilities within its global network, with 136 facility license approvals and a 100% success in GMP inspections. Its world-class quality and compliance capabilities remain the cornerstone of clients’ trust.

Global Layout: Building Strategic Hubs in the U.S., Singapore and Qatar

WuXi Biologics is increasing strategic investments in the U.S. to deliver integrated biologics services. By leveraging cross‑site synergies among facilities in New Jersey and Massachusetts, the company enables the seamless transfer of materials, samples, and products across the U.S..

In Singapore, the company has commenced construction of its new modular drug product facility, while the drug substance modular facility is currently in the design phase. Meanwhile, its subsidiary WuXi XDC achieved mechanical completion of its Singapore manufacturing facility in June 2025, positioning the Singapore site as a strategic hub within the global network.

In December 2025, WuXi Biologics announced the signing of an MOU with the Qatar Free Zones Authority (QFZ). The long-term strategy is to establish the Qatar site as a strategic pillar within WuXi Biologics’ global CRDMO network, marking the company’s entry into the region while extending its global footprint and capabilities.

Global Leading Digital CRDMO: Powering World-class Speed, Quality, Operational Efficiency and Client Experience

WuXi Biologics has embedded digital innovations into every fabric of research, development, manufacturing, operations and customer engagement that truly redefined values for its partners.

The DaVinci Client Portal provides a secure, real-time interface for proposal generation, access to experimental and manufacturing data and reports, cost estimates, and shipment tracking. Lab core systems, such as BioFoundry and InSilico, accelerate discovery, development and manufacturing by enabling digital twins, in‑silico modeling and predictive decision-making. By leveraging smart manufacturing solutions, such as Electronic Batch Record (EBR), the company has driven an approximately 40% productivity gain and ensured data integrity and high product quality, while advanced planning systems have delivered about a 20% improvement in efficiency. Recently, WuXi Biologics launched the industry-leading digital twin platform PatroLabTM to enhance process performance, minimize process risks, shorten development timelines, and ensure consistent, high-quality biologics manufacturing.

A Leader in Industry Sustainability

As a participant of the United Nations Global Compact (UNGC), WuXi Biologics has made significant strides in sustainability, earning widespread industry recognition. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP “A List” for Climate Change, Water Security, Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

Sustainable High Growth in 2026

In 2026, WuXi Biologics will build on strong momentum with accelerated growth driven by robust research, leading development and explosive manufacturing business. By putting clients first and leveraging its full end‑to‑end capabilities, WuXi Biologics is fast‑tracking biologics innovation for global clients and delivering meaningful benefits to patients around the world.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

Media
PR@wuxibiologics.com

Business
info@wuxibiologics.com

 

US Suspends Immigrant Visa Processing for 75 Countries, Thailand, Cambodia on the List

This photo is used for representational purpose only.

AFP – The United States said on 14 January it was suspending the processing of immigrant visas from 75 countries, President Donald Trump’s latest move against foreigners seeking to come to America.

The United States has long rejected visas from people who appear likely to end up needing government welfare, but the State Department said it would now use the same authority for a blanket suspension of immigrant visas based on nationality.

“The Trump administration is bringing an end to the abuse of America’s immigration system by those who would extract wealth from the American people,” State Department spokesman Tommy Pigott said.

“Immigrant visa processing from these 75 countries will be paused while the State Department reassesses immigration processing procedures to prevent the entry of foreign nationals who would take welfare and public benefits,” he said.

White House Press Secretary Karoline Leavitt posted on X that the countries affected would include Somalia, whose people Trump has attacked in heated terms after immigrants were involved in a funding scandal in Minnesota, as well as Russia and Iran.

A US official said that the other countries affected would include a number of countries with friendly relations with the United States, including Brazil, Egypt and Thailand.

Other countries to face the pause include Nigeria, Africa’s most populous country, as well as Iraq and Yemen, the official said.

The State Department did not immediately release a full list of countries.

The freeze will begin on 21 January with no set time for it to end, the US official, who was not authorized to speak to the press, said on condition of anonymity.

Trump has made no secret of his desire to reduce immigration by people who are not of European descent. He has described Somalis as “garbage” who should “go back to where they came from” and instead said he was open to Scandinavians moving to the United States.

The State Department said Monday that it has revoked more than 100,000 visas since Trump’s return, a one-year record.

The Department of Homeland Security last month said that the Trump administration has deported more than 605,000 people, and that 2.5 million others left on their own.

The latest move does not affect tourist, business or other visas, including for soccer fans seeking to visit for this year’s World Cup, although the Trump administration has vowed to vet all applicants’ social media histories.


© Agence France-Presse